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Injury to the skin causes a breach in the protective layer surrounding the body. Many pathogens are resistant to antibiotics,
rendering conventional treatment less eﬀective. This led to the use of alternative antimicrobial compounds, such as silver ions,
in skin treatment. In this review nanoﬁbers, and the incorporation of natural antimicrobial compounds in these scaﬀolds, are
discussed as an alternative way to control skin infections. Electrospinning as a technique to prepare nanoﬁbers is discussed. The
possibility of using these structures as drug delivery systems is investigated.
1.Introduction
Severe skin damage and loss of the protective layer exposes
underlying tissue to secondary infections [1, 2]. In the
United States, treatment of ﬁre and burn wound infections
amount to more than 7.5 billion US dollars per annum [3].
From one million patients, an estimated 10000 die from
secondary microbial infections [2, 4–9]. If wounds are not
treated eﬀectively, pathogens form bioﬁlms, rendering them
resistant to antibiotics [10–13]. In severe cases, bioﬁlms need
to be surgically removed to prevent further infection [14].
Staphylococcus aureus, including methicillin resistant
strains (MRSA), are the most prevalent in skin infections.
Pseudomonas aeruginosa, Escherichia coli, Acinetobacter spp.,
and coagulase-negative staphylococci have also been isolated
from skin lesions [15–19]. More than 95% of S. aureus
strains are resistant to penicillin and 60–70% are resistant
to methicillin [20–22]. Methicillin resistance is attributed to
the mec A gene encoding penicillin binding proteins [20, 23].
These proteins occur in the cell wall and play a role in
the synthesis of peptidoglycan and are usually inactivated
by beta-lactam antibiotics. However, in MRSA the mec A
gene encodes a low-antibiotic aﬃnity penicillin binding
protein, known as PBP2a, conferring methicillin resistance
to the cells [20]. Some MRSA strains are also resistant
to tetracyclines, sulphonamides, trimethoprim, macrolides,
aminoglycosides, mupirocin, mafenide acetate,silver sulpha-
diazine, bacitracin, ciproﬂoxacin, and vancomycin [24–29].
Vancomycin-resistant enterococci and P. aeruginosa strains
resistant to several antibiotics have also been reported [30].
This review focuses on the treatment of skin infections
and open wounds and the biomedical application of elec-
trospun nanoﬁbers, with speciﬁc emphasis on antimicrobial
delivery systems. Antimicrobials other than antibiotics are
discussed.
2. CurrentTreatment of Skin
Infections and Drawbacks
Most data on skin infections are from publications on
burn wounds. Several treatments have been proposed. Silver
sulfadiazine, a combination of silver nitrate and sodium
sulfadiazine, has been used to treat invasive burn wound
sepsis [6, 14, 32, 33]. With prolonged use, silver ions may be
toxic, as it binds to DNA and prevents replication [34, 35].
Furthermore, some pathogens have developed resistance to
silver [36–38].
Mafenide acetate and chlorexidine digluconate creams
have been used to treat burn wound infections [14, 39].2 Journal of Biomedicine and Biotechnology
The disadvantage of these topical creams is that they have to
be applied twice daily. If incorporated in wound dressings,
the bandages have to be changed daily, which may expose
the wound to further infection [40]. As in the case of many
other antimicrobials, pathogens with resistance to mafenide
acetate have been reported, especially when used over an
extended period [27]. Mupirocin has also been used in the
treatment of burn wound infections [41].
Nanotechnology oﬀers the latest alternatives to wound
dressings, of which Acticoat A.B, Silverlon, and Silvasorb
with nanoparticles are good examples. Supporters of this
technology claim that the nanocrystalline silver particles
are released in a controlled manner, inhibiting the growth
of a broad spectrum of pathogens [43–45]. Entrance of
the nanoparticles into cells and their mode of action
is summarized in Figure 1. Endosomes, ﬁlled with silver
nanoparticles, lysosomes, and silver nanoparticles in the
nucleus of treated cells, have been observed. Cells may also
take up silver nanoparticles via endocytosis.
Some concerns exist regarding the medical use of silver
particles, as they form reactive oxygen species (ROS),
reduce ATP, and damage mitochondria and DNA [31, 46].
Furthermore, silver nanoparticles caused an inﬂammatory
response in a murine model system [47]. Silver nanoparticles
are, however, less toxic compared to gold nanoparticles, as
observed in experiments with J774 A1 murine macrophages
[48].
3. Production of Nanoﬁbers
Nanoﬁbers are produced from polymers treated in a speciﬁc
manner to form threads of a few micrometers to nanometers
indiameter.Thelargesurfacetovolumeratio,andmanipula-
tionofsurfaceproperties,rendersnanoﬁberstheidealmatrix
to develop super ﬁne structures [49–51]. The possibility to
immobilizeantibiotics,enzymes,antimicrobialpeptides,and
growth hormones to nanoﬁbers, or encapsulation into ﬁber
matrixes, opens a new ﬁeld in biomedical engineering [52–
60].
Several methods are used to produce ultra ﬁne ﬁbers,
for example, self assembly of polymers, template synthesis,
phase separation, and electrospinning [49, 62–66]. Electro-
spinning, schematically presented in Figure 2, is the most
cost eﬀective and easiest way to produce large volumes of
nanoﬁbers. One electrode is placed in a polymer solution
and the other electrode is linked to a collector, which is
usually a stationary or rotating metal screen, plate, or wheel.
The electrically charged polymer forms a Taylor cone at
the tip of the needle and is ejected at a speciﬁc charge.
As the polymer solution accelerates, the solvent evaporates
and nanoﬁbers are formed. Fibers are aligned by using a
rotating collector, an auxiliary electrical ﬁeld, or a rotating
collector with a sharp edge and a rapidly oscillating frame
[67–71]. Coaxial electrospinning (Figure 3(a)) is used to
produce nanoﬁbers with a core-shell structure (Figure 4(a)),
which is ideal for encapsulating hydrophilic molecules.
Coaxial spun ﬁbers have a high loading eﬃciency [56, 72].
Emulsion electrospinning is also used to produce core-shell-
structured nanoﬁbers (Figures 3(b) and 4(b)). An emulsion
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Figure 1: Illustration of the uptake of silver nanoparticles, via
endocytosis, and the mechanisms by which they cause toxicity to
cells [31].
is prepared by emulsifying an aqueous phase, which contains
a hydrophilic polymer or molecule to be encapsulated, into
an organic phase containing a polymer that forms the shell
[42, 61]. The emulsion is then electrospun into core-shell-
structured nanoﬁbers (Figure 4(b)).
4. ParametersThat Inﬂuence Nanoﬁber
Formation andtheElectrospinningProcess
The quality and characteristics of the ﬁnal product are
determined by the temperature, viscosity, elasticity, con-
ductivity, and surface tension of the solution, strength
of the electric ﬁeld, distance between the needle tip and
collector, and humidity [49, 73, 74]. Larger ﬁbers (bigger
diameter) are obtained by increasing the concentration of
the polymer in solution. Polyvinylpyrrolidone (PVP) at
4% (w/w) in a 50:50 (w/w) dimethylformamide:ethanol
solution is used to produces ﬁbers of 20nm in diameter
[75]. However, PVP at 8% (w/w) in the same solu-
tion produces ﬁbers of 50nm in diameter, and PVP at
10% (w/w) produce ﬁbers of 300nm in diameter. Elec-
trospinning diﬀerent concentrations of poly L-lactic acid
(PLLA) in a chloroform solution produce nanoﬁbers with
diﬀerent morphologies (Figure 5). PLLA of 1% (w/w)
produces a “bead on a string” structure whereas 3%
(w/w) PLLA forms nanoﬁbers with a smooth structure
[61].Journal of Biomedicine and Biotechnology 3
Polymer solution
Polymer jet
Collector with non-woven ﬁber mat
High voltage
10μm
Figure 2: Schematic representation of the electospinning process.
Solvents inﬂuence the surface tension and viscosity
of the solution and aﬀect the morphology of ﬁbers [75,
76]. PVP (4%, w/w) dissolved in dichloromethane (MC)
forms ﬁbers with spindle-like beads and hollow or solid
structures whereas the same concentration PVP in N,N-
dimethylformamide (DMF) forms sphere-like beads with
solid structures. PVP dissolved in ethanol yields smooth
ﬁbers with a diameter ranging from 100 to 625nm [75]. The
PVP/DMF and PVP/MC solutions have a high surface ten-
sion (47.1 and 38.7 centipoise, resp.) and low viscosity (9.8
and 13.0 centipoise, resp.). A PVP/ethanol solution, on the
other hand, has a low surface tension (29.3 centipoise) and
high viscosity (17.3 centipoise). Diﬀerent solvents evaporate
at diﬀerent speeds and aﬀect the structure of the ﬁbers [76].
Changes in current may also aﬀect the morphology of ﬁbers,
as observed with polyethylene oxide (PEO). An increase
from 5.5kV to 9.0kV changed the morphology of the PEO
ﬁbers from smooth to a “bead on a string” structure [74].
The importance of processing variables that inﬂuence ﬁber
morphology during electrospinning is reviewed by Deitzel
et al. [74].
5. ElectrospunNanoﬁbers inBiomedical
Engineeringas Drug DeliveryVehicles
Natural and synthetic polymers have been spun into
nanoﬁbers for potential use in biomedical engineering [53,
54, 61, 76–79]. Chitin, a structural polysaccharide from
arthropods, yielded ﬁbers ranging from 40 to 600nm in
diameter [79]. A combination of water-soluble carboxyethyl
chitosan and poly-vinyl alcohol (PVA) was electrospun to
produce a wound dressing. The nanoﬁbers revealed no
toxicity when tested with a mouse ﬁbroblast L929 cell
line, and promoted cell attachment and proliferation [78].
Chitosan acetate bandages proved eﬀective as an antimi-
crobial dressing when tested on BALB/c mice with burn
wounds that have been infected with P. aeruginosa and
Proteus mirabilis [80].
Hydrophilic and hydrophobic polymer blends have also
been spun into biodegradable nanoﬁbers. The hydrophobic
p o l y m e rp r o v i d e st h es t r u c t u r eo r“ b a c k b o n e ”a n dd e g r a d e s
over a long period whereas the more hydrophilic poly-
mer degrades or dissolves faster. The choice of polymer
or polymer blends play an important role in devices
aimed at controlled release. Examples of using hydrophilic
and/or hydrophobic polymers for the controlled release
of molecules, for example, antibiotics, plasmids, growth
factors, proteins, silver particles, bacteria and viruses will be
discussed in more detail [54, 61, 82, 83, 89, 93].
5.1. Antibiotics. Rifampin, encapsulated in PLLA during
electrospinning, and incubated in a 0.05M Tris-HCl buﬀer,
was only released when proteinase K was added to the solu-
tion. This suggests that the release of rifampin was initiated
by the degradation of PLLA and not by normal diﬀusion
[81]. In another experiment, doxorubicin hydrochloride and
paclitaxil were encapsulated into PLLA nanoﬁbers [81].
Doxorubicin hydrochloride was detected on the surface
of the nanoﬁbers but paclitaxil remained encapsulated.
Rifampin and paclitaxil were more soluble in the chloro-
form/acetone solvent compared to doxorubicin hydrochlo-
ride. The solubility of the molecule to be encapsulated in the
polymer solvent plays an important role in its distribution
throughout the nanoﬁbers. Tetracycline hydrochloride (5%,
w/w) encapsulated in poly-ethylene-co-vinyl acetate (PEVA),
or in a blend of PEVA and PLLA, has a relatively slow
and consistent release rate [60] .T h eP E V Aa n dP E V A / P L L A
blend containing 5% (w/w) tetracycline hydrochloride had4 Journal of Biomedicine and Biotechnology
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Figure 3: (a) Schematic representation of the needle setup used in
coaxial electrospinning and (b) representation of the formation of
core-shell structured nanoﬁbers by emulsion electrospininng [42].
a similar release rate to Actisite, a commercial drug deliv-
ery system, following the initial high burst release. The
antibiotic Mefoxin (cefoxitin sodium) was encapsulated in
poly-lactate-co-glycolide (PLGA) ﬁbers and in ﬁbers consist-
ing of a poly-lactate-co-glycolide/polyethylene glycol-block-
poly(L-lactide) copolymer (PLGA/PEG-b-PLLA). Mefoxin
released from the ﬁbers inhibited the growth of S. aureus in
culture and on an agar surface. PEG-b-PLLA prolonged the
drug release for up to one week [82].
5.2. Plasmid DNA. The feasibility of encapsulating plasmid
DNA in electrospun nanoﬁbers and to use these nanoﬁbers
asgenedeliveryvehicleshasalsobeenshown[83].PLGAand
a PLA-PEG block copolymer was electrospun with a 7164bp
plasmid (pCMVβ), encoding β-galactosidase. The majority
of plasmid DNA was released over 20 days. The bioactivity
of pCMVβ was evaluated by conducting transfection experi-
ments with preosteoblastic MC3T3 cells.The β-galactosidase
gene was successfully expressed by preosteoblastic MC3T3
cells that have taken up the plasmid.
5.3. Growth Factors. Human β-nerve growth factor (NGF)
was encapsulated into ﬁbers consisting of a copolymer of
poly ε-caprolactone and ethyl ethylene phosphate (PCLEEP)
through electrospinning [54]. The bioactivity of NGF was
evaluated by incubating rat pheochromocytoma (PC 12)
cells in the supernatant of nanoﬁbers containing encapsu-
lated NGF and searching for diﬀerentiation into neurons.
Bioactivity was recorded for up to three months. Human
glialcell-derived neurotrophic factor (GDNF), encapsulated
intoPCLEEPnanoﬁbers,wasreleasedinactiveformforupto
two months [84]. A 15mm nerve lesion was made in the left
sciatic nerve of 3.5month-old Sprague–Dawleyrats. The rats
then received longitudinally aligned ﬁbers impregnated with
GDNF. Longitudinally or circumferentially aligned ﬁbers
with no GDNF encapsulated within served as controls. In
ratsthatreceivedencapsulatedGDNF,abridgeformedacross
the lesion and the nerve was regenerated after three months.
However, the nerve system in only half the number of rats
that received control ﬁbers was regenerated. The stimulation
of bone regeneration in nude mice that have been treated
with bone morphogenetic protein-2 (BMP-2) encapsulated
in PLGA-hydroxyapatite (HAp) nanoﬁbers was also shown
in [85]. Bioactive BMP-2 was released from the nanoﬁbers
over four weeks.
5.4. Proteins. Lysozyme was encapsulated in biodegrad-
able poly-ε-caprolactone (PCL) and PEO ﬁbers [53]. The
highest release of lysozyme (87% over 12 days) was
recorded in a PEO/PCL nanoﬁber with a 90/10 ratio. The
released lysozyme maintained 90% of its catalytic activity.
Cytochrome C has been encapsulated in nanoﬁbers by
emulsionelectrospinning [61].Thiswasdone byemulsifying
an aqueous solution of cytochrome C in a chloroform
solution containing PLLA. High encapsulation eﬃciencies
(85% to 95%) were recorded after spinning. However, low
levels of cytochrome C were released. Controlled release
was obtained when PLLA was blended with poly(L-lysine)
(PLL)andpoly(ethyleneimine)(PEI),hydrophilicpolymers.
A blend containing 50% PLL released most of the protein
(75%) with a high initial burst release.
5.5. Bacteria and Viruses. Escherichia coli, Staphylococcus
albus, and bacteriophages T7, T4, and λ were encapsulated
in PVA nanoﬁbers with water as solvent [88]. The encapsu-
lated cells and bacteriophages survived the electrospinning
process and remained viable for three months at −20 and
−55
◦C. M13 viruses were encapsulated into PVP nanoﬁbers
[91]. The ﬁbers were dissolved in a tris-buﬀered saline
solution (pH 7.5). The released viruses were still able to
infect bacterial cells. Micrococcus luteus and E. coli were
encapsulated into PEO nanoﬁbers with water as solvent
[89]. Up to 74% of the M. luteus cells, but only 0.1%Journal of Biomedicine and Biotechnology 5
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Figure 4: Core-shell structured nanoﬁbers produced from (a) coaxial electrospun PEO and poly-dodecyl thiophene (PDT), with PDT
forming the core structure [23] and (b) emulsion electrospun poly(ethylene glycol)-poly(L-lactic acid) diblock copolymer (PEG750-PLA)
and PEO (the core is visible by labeling PEO with ﬂuorescein isothiocyanate, FITC) [24].
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Figure 5: Fibers produced from electrospinning with (a) 1% (w/w) PLLA (the “bead on a string” morphology is clearly visible) and (b) 3%
(w/w) PLLA, showing a smooth structure [61].
of the E. coli cells, survived the electrospinning process.
We recently reported on the encapsulation of a probiotic
lactic acid bacterium in electrospun PEO nanoﬁbers [90].
Only 2% of the Lactobacillus plantarum cells survived the
electrospinnig process. However, the cells that survived were
still able to produce the antimicrobial peptide (bacteriocin)
and inhibited the growth of E. faecium HKLHS that served as
target strain.
5.6. Silver Nanoparticles. Silver nanoparticles were incorpo-
rated in cellulose acetate nanoﬁbers by electrospinning cellu-
lose acetate with 0.5wt% AgNO3 [94]. Silver particles were
generated on the surface of the nanoﬁbers after irradiation
at 245nm. Almost all viable cells (99.9%) of Gram-positive
bacteria, E. coli, Klebsiella pneumoniae,a n dP. aeruginosa
were killed after 18 hours of exposure to the encapsulated
silver particles. Silver-loaded zirconium phosphate was spun
into poly ε-caprolactone ﬁbers [86]. Growth inhibition of
up to 99.27% of S. aureus and up to 98.44% of E. coli was
recorded when the strains were cultured in the presence of
these nanoﬁbers. Human dermal ﬁbroblasts that attached to
the nanoﬁbers continued to proliferate, suggesting that the
ﬁbers may be used as wound dressings. Similar ﬁndings have
also been reported by Rujitanaroj et al. [95]. However, some
authors have reported that silver may elicit toxic side eﬀects
on human cells as discussed elsewhere in this paper. Table 1
summarizes various molecules that have been encapsulated
into synthetic and natural polymers, or blends thereof, by
electrospinning to facilitate their release.
6. NaturalAlternativesto Antibiotics
Lactic acid bacteria (LAB) are a diverse group of organisms
with GRAS (generally regarded as safe) status and have
been consumed over decades [96]. Most species produce
bacteriocins, that is, ribosomally synthesized proteins or
protein complexes with bacteriostatic or bactericidal activity
against closely related species [97, 98] .T h ep e p t i d e sh a v ea
net positive charge (cationic) and are amphiphilic or rather
more hydrophobic. They intercalate into the cell membrane
of sensitive cells, form pores and disrupt the proton motive
force (PMF) [99–101].
Bacteriocins are classiﬁed into two major classes. Class
I contains the lantibiotics that are small peptides that
undergo posttranslational modiﬁcations and have lanthio-
nine or β-methyllanthionine residues, for example, nisin,
merscadin [102, 103]. Class II contains the nonlanthionine-
containing bacteriocins that are small (<10kDa) heat-stable6 Journal of Biomedicine and Biotechnology
Table 1: Molecules and organisms encapsulated into electrospun nanoﬁbers.
Encapsulated molecules Polymer/polymer blends Reference
Antibiotics
Rifampin PLLA [81]
Doxorubicin hydrochloride PLLA [81]
Paclitaxil PLLA [81]
Tetracycline hydrochloride PEVA [60]
Mefoxin PLGA/PEG-b-PLLA [82]
Plasmid DNA
pCMVb encoding a β-Galactosidase PLGA and PLA-PEG [83]
Growth Factors
Human β-nerve growth factor (NGF) PCLEEP [54]
Human glialcell-derived neurotrophic factor (GDNF) PCLEEP [84]
Bone morfogenetic protein-2 (BMP-2) PLGA-Hap [85]
Antimicrobial compounds
Silver nanoparticles Cellulose acetate [72]
PCL/silver-loaded zirconium phosphate [86]
Proteins
BSA PEO [87]
Lysozyme PCL/PEO [53]
Lysozyme PCL/PEG [77]
Cytochrome C PLLA/PLL [61]
Bacteria
Eschericia coli
Staphylococcus albus PVA [88]
Micrococcus luteus
Eschericia coli PEO [89]
Lactobacillus plantarum PEO [90]
Bacteriophages
T7
T4
λ PVA [88]
M13 PVP [91]
PLLA: poly (L-lactide); PEVA: poly-ethylene-co-vinyl acetate; PLGA: poly-lactate-co-glycolide; PEG: polyethylene glycol; PLGA/PEG-b-PLLA: poly-
lactate-co-glycolide/polyethylene glycol-block-poly(L lactide); PCL: poly ε-caprolactone; PCLEEP: poly ε-caprolactone ethyl ethylene phosphate; Hap:
Hydroxyapatite; PEO: polyethylene oxide; PDLA: poly(D,L-lactide); PLL: poly(L-lysine); PVA: poly(vinyl alcohol); PVP: polyvinylpyrrolidone.
Table 2: Classiﬁcation system for bacteriocins [92].
Classes Characteristics
Class I Lantibiotics
Class Ia Small (19–38 amino acids), elongated, positively charged peptides that form pores
Class Ib Globular peptides that interfere with essential enzymes
Class II Nonlanthionine containing-bacteriocins
Class IIa Pediocin-like peptides that contain the YGNGVXCXXXXVXV consensus sequence in their N-terminal
Class IIb Two-peptide bacteriocins, require both peptides for activity
Class IIc Cyclic peptides, N- and C-terminal of peptides are covalently linked
Class IId Single non-pediocin like peptides
peptides that do not undergo extensive post-translational
modiﬁcations [92]. Examples include pediocin PA-1/AcH,
plantaricin S, enterocin AS-48, and lactococcin A [104–107].
TheclassesandsubclassesofbacteriocinsarelistedinTable 2.
Some bacteriocins, such as mersacidin, have shown
activity towards MRSA that have been associated with
various hospital acquired infections [108]. Nisin F was also
investigated as treatment for subcutaneous skin infectionsJournal of Biomedicine and Biotechnology 7
caused by S. aureus [109]. Bacteriocins are thus attractive
natural alternatives to antibiotics, which can be used in
the treatment of bacterial infections. A localized delivery
system is, however, required to control the level and rate of
bacteriocinsdeliveredtothewound.Anovelapproachwould
be to encapsulate bacteriocins into electrospun nanoﬁbers
and use this as wound dressings for burned victims.
The feasibility of encapsulating bacteriocins into elec-
trospun nanoﬁbers was recently reported in [90]. The
bacteriocin plantaricin 423 retained activity after electro-
spinning and inhibited the growth of E. faecium HKLHS
and Lactobacillus sakei DSM 20017 that served as target
strains. Nisin, a bacteriocin produced by Lactococcus lactis,
was successfully loaded in PLLA nanoparticles by using
semicontinuous compressed CO2 antisolvent precipitation
[110]. Nisin was released in the active form and exerted its
antibacterial activity up to 45 days, when incubated with a
culture of Lactobacillus delbrueckeii.
7. Conclusion and FutureTrends
Electrospinning is a versatile and relatively easy technique to
produce large amounts of nanoﬁbers with diverse molecules
encapsulated within. The large surface to volume ratio of
nanoﬁbers allows the encapsulation of high concentrations
of bacteriocins and direct delivery to sites of skin infection.
The use of bacteriocins to control infections may help to
prevent further increase in antibiotic resistance amongst
bacteria and may prevent negative side eﬀects some current
medication has on patients. Release of bacteriocins from
nanoﬁberscanbecontrolledbyselectingpolymersofspeciﬁc
composition. Furthermore, speciﬁc nanoﬁber scaﬀolds can
be designed that are oxygen permeable and structurally
similar to the extracellular matrix (EM) in skin.
Ideally, nanoﬁber wound dressings should not only
contain antimicrobial agents, but a combination of com-
pounds that would accelerate the healing process and
alleviate discomfort. Such compounds may include anti-
inﬂammatory and tissue repairing drugs. Although anti-
inﬂammatory drugs have been encapsulated into nanoﬁbers,
no reports have been published on the encapsulation of
combined compounds.
Future research has to focus on developing nanofber
wound dressings containing a combination of antimicrobial
compounds, anti-inﬂammatory drugs, and painkillers. Fur-
thermore, the nanoﬁber scaﬀold has to be designed to allow
controlled released of the drugs over an extended period to
avoid frequent changes of wound dressings. The toxicity of
nanoﬁbers needs to be researched, that is, much more in vivo
studies need to be performed.
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